Sodium glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have proven benefits in cardiovascular and kidney outcomes, with some notable differences in outcomes such as heart failure and stroke. This evidence concerns the gene GLP1R and heart failure.